'Optimistic' Pfizer chief won't rule out Astra break-up
Wednesday 14 May 2014
Pfizer chief executive Ian Read is “optimistic” about gaining control of AstraZeneca, but won’t rule out breaking up the British drugmaker if his bid is successful.
“I never use the word hostile,” Read told the London Evening Standard amid expectations that a knock-out offer could be pitched direct to the British firm’s investors.
“We are talking to shareholders, we would like to talk to AstraZeneca… and we are still hopeful of an accommodation,” but meanwhile “we are considering all of our options, of course”.
Read, who today appeared before the Science and Technology Committee before touring City shareholders, said it was important for Viagra-maker Pfizer to win over politicians and the public because: “We want to be welcome in any country we are in. We don’t want to be fighting against society.”
He rejected claims that David Cameron had been cheerleading for his bid: “I believe the government is not supportive of either company, they are supportive of doing science in the UK.”
Read believes AstraZeneca boss Pascal Soriot “had a tough hand dealt” but had created “an interesting pipeline” of drugs.
He said, however: “You don’t transform your pipeline in 15 months. To build a pipeline you need five to six years. I think obviously there are interesting assets in AstraZeneca. I think they are far more interesting if they are combined with our portfolio.”
Read said his own shareholders “understand our position” but of course “they will not reward us if we overpay” for his prey.
US giant Pfizer has until May 26 to bid. Analysts believe the merged company could be carved up along product lines, as Kraft was following its controversial Cadbury takeover.
“I have not said I have got any intention of splitting this company up,” Read said, adding: “If at some point shareholders say to us, we don’t think you are running all of these businesses optimally and we think you could increase value by one of them being sold, well that is a possible option.”
Read told the select committee that Pfizer’s and AstraZeneca’s “science will continue” and that the enlarged group would be a world powerhouse in cancer drugs.
For the second day running, Soriot faced MPs after Read had been grilled by them. He warned that the group’s research work could “quickly lose momentum” because of the distraction of a merger.
- 1 Venezuela Expo Tattoo 2015: Extreme body art from 'Vampire Woman' to 109mm earlobes
- 2 Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
- 3 Ball pool for adults opens in London
- 4 Game of Thrones season 5 trailer: The first full-length look is here
- 5 Rashida Jones speaks out against male-centric porn saying 'women should have sex and feel good about it'
Boris Johnson claims porn-obsessed Islamic jihadists are 'literally w*****s'
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
Putin opponent reveals Russian President's daughter's secret identity
Ball pool for adults opens in London
Amal Clooney gives excellent response to fashion question at European Court of Human Rights
9 reasons Greece's experiment with the radical left is doomed to failure
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
King Abdullah dead: We can't afford not to hold Saudi Arabia's royals to account
iJobs Money & Business
£40000 - £50000 per annum: Recruitment Genius: This is an exciting opportunity...
£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...